Tatva Chintan Q1 Review – Near Term Pressure In SDAs; Working On Multiple Opportunities: Nirmal Bang

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Tatva Chintan Pharma Chem Ltd.’s Q1 FY23 Ebitda came in ~29% below our estimate on account of higher-than-expected pressure in structure directing agents revenue and forex loss of ~Rs 50 million.

SDA revenue contribution fell significantly to ~7% in Q1 FY23 versus ~52% in Q1 FY22. Revenue (ex-SDA) grew by ~60% YoY wherein all the sub-segments namely, phase transfer catalysts, pharmaceutical and agrochemical intermediates and other specialty chemicals and electrolyte salts grew significantly.

SDA sales were affected by semiconductor issues, geopolitical situation in Europe and extended lockdowns in China due to Covid-19 outbreak. The management expects significant improvement in SDA sales from Q4 FY23 onwards.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.